Cat. No. 6004
Chemical Name: 6-(2,5-Dimethoxyphenyl)-3,4-dihydro
Biological ActivitySelective myeloperoxidase (MPO) inhibitor (IC50 = 1.5 μM in LPS-stimulated human whole blood). Selective for MPO over a panel of 50 receptors, enzymes, ion channels and transporters, including thyroid peroxidase. Inhibits MPO activity in peritoneal lavage and plasma in a murine peritonitis model. Also reduces lung edema in a murine pulmonary immune complex vasculitis model. Orally bioavailable.
Licensing InformationSold for research purposes under agreement from Pfizer Inc
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Ruggeri et al (2015) Discovery of 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases. J.Med.Chem. 58 8513. PMID: 26509551 .
Zheng et al (2015) PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J.Pharmacol.Exp.Ther. 353 288. PMID: 25698787 .
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PF 06281355 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PF 06281355, supplier, PF06281355, myeloperoxidase, inhibitors, inhibits, selective, orally, bioavailable, vasculitis, Tocris Bioscience, Other Oxygenase/Oxidase Inhibitor products
Find multiple products by catalog number
April 1 - 5, 2017
Washington, D.C., USA